Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects

@article{MacDonald2004DoxazosinFT,
  title={Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects},
  author={Roderick MacDonald and Timothy J. Wilt and Richard W Howe},
  journal={BJU International},
  year={2004},
  volume={94}
}
The first paper in this section is a systematic review of the efficacy and adverse effects of doxazosin for treating LUTS compatible with benign prostatic obstruction. The criteria for inclusion were met by 13 studies involving 6033 men. The authors found evidence that doxazosin was effective and well tolerated in patients with LUTS. Combined therapy was superior to doxazosin alone in reducing the risk of clinical progression and other long‐term complications of this condition. 
Doxazosin in the treatment of benign prostatic hypertrophy: an update
TLDR
Combination therapy improved LUTS and reduced the risk of overall clinical progression of BPH compared to each drug separately in men followed over 4 years and comparable with other a1–blockers.
Lower urinary tract symptoms in men
TLDR
Multiple clinical trials have shown that α adrenoceptor antagonists can significantly ameliorate lower urinary tract symptoms and reverse the natural course of BPH, reducing the risk of urinary retention and the need for surgical intervention.
Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
TLDR
Evidence suggests that this combination of tadalafil and finasteride may be particularly effective in reducing treatment-related sexual adverse events associated with 5-ARI treatments.
Drug treatment for lower urinary tract symptoms
TLDR
Long-term combination therapy with alpha-1-blockers and 5α-reductase inhibitors reduces the risk of the overall clinical progression of BPH significantly more than does treatment with either drug alone.
THERAPEUTIC APPROACHES TO BPH
TLDR
Drugs such as selective alpha adrenergic blockers have been useful in improving the quality of life in BPH patients and combination with 5 alpha reductase inhibitors, botulinum toxin A have brought about significant improvement in the alleviation of outflow symptoms.
The Diagnosis and Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia with α-Blockers: Focus on Silodosin
TLDR
Silodosin is administered once daily and provides rapid improvements in the signs and symptoms of moderate to severe LUTS/BPH in male patients, and is a welcome addition to the pharmacological options for these patients.
Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management
TLDR
CombAT is the first study to show benefit in improving BPH symptoms for combination therapy over the alpha‐blocker, tamsulosin, from 9 months of treatment and a preplanned 2‐year analysis has shown sustained symptom improvement with combination therapy, significantly greater than with either monotherapy.
...
...

References

SHOWING 1-10 OF 46 REFERENCES
A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients
TLDR
The efficacy and safety of an incremental‐dose regimen of terazosin and a fixed‐ dose regimen of tamsulosin on Japanese patients with symptomatic benign prostatic hyperplasia (BPH) are compared.
A randomized, double‐blind crossover study of tamsulosin and controlled‐release doxazosin in patients with benign prostatic hyperplasia
To compare the effects of the doxazosin gastrointestinal therapeutic system, extended‐release (doxazosin‐GITS) formulation, and tamsulosin, another α1‐antagonist, on total International Prostate
Doxazosin Treatment in Patients with Prostatic Obstruction
The safety and efficacy of the selective alpha1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and
A three month double‐blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction
TLDR
Doxazosin was well-tolerated and produced both urodynamic and symptomatic improvement in men with BPH, thereby providing a satisfactory alternative to existing drugs with the additional benefit of once daily dosage.
Comparative efficacy of two α1‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement
TLDR
To compare doxazosin and alfuzosin in patients with moderate to severe lower urinary tract symptoms (LUTS) suggestive of bladder outlet obstruction, the objective was to establish an apples-to- apples comparison study.
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
TLDR
Tamsulosin is the first adrenoceptor antagonist that is selective for the alpha 1 A-subtype in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction, and this specificity may explain its lack of effect on blood pressure compared with alfuzosin.
Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study.
TLDR
In conclusion, doxazosin 4 mg once daily is safe and effective in relieving symptoms in patients with BPH.
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
TLDR
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
...
...